Astragalin, which showed strong cytotoxicity against cancer cells (Chen et al., 2017), exhibited a non-significant difference compared to Nutlin in normal cells (p = 0.9796), suggesting a comparable safety profile to the reference MDM2 inhibitor. Here, MDM2 is linked to cancer.